文献速递泌尿男性生殖肿瘤

转移性去势抵抗性前列腺癌患者阿比特龙血浆谷浓度与前列腺特异性抗原反应的关系

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Cancer · 2016-12-24

单中心前瞻性观察研究纳入61例接受阿比特龙治疗的转移性去势抵抗性前列腺癌患者,测定稳态血浆谷浓度。38例(62%,95%CI 50-78)出现PSA反应,反应者阿比特龙谷浓度较无反应者高1.5倍(12.0 ng/mL vs 8.0 ng/mL,P=0.0015),多因素分析仅谷浓度与PSA反应独立相关(OR=1.12,95%CI 1.01-1.25,P=0.004)。谷浓度最佳阈值为8.4 ng/mL,高于该阈值者无进展生存期显著更长(HR=0.55,95%CI 0.31-0.99,P=0.044)。

要点

  • 阿比特龙谷浓度在PSA反应者中为12.0 ng/mL,较无反应者的8.0 ng/mL高1.5倍(P=0.0015)。
  • 多因素分析仅阿比特龙谷浓度与PSA反应独立相关(OR=1.12,95%CI 1.01-1.25)。
  • 谷浓度高于8.4 ng/mL者无进展生存期显著更长(HR=0.55,95%CI 0.31-0.99)。

核心结论

  • 阿比特龙谷浓度与PSA反应及无进展生存期相关,并确定了PSA反应的血浆浓度阈值。
  • 作者认为阿比特龙浓度监测是改善转移性去势抵抗性前列腺癌患者临床结局的新方法。

研究设计与样本

  • 单中心前瞻性观察研究,2012年至2016年纳入61例接受阿比特龙治疗的转移性去势抵抗性前列腺癌患者进行药代动力学/药效学评估。
  • 采用液相色谱-荧光检测法测定稳态阿比特龙血浆浓度,主要目标为研究平均阿比特龙血浆暴露(ABI Cmin)与3个月PSA反应的关系。

主要发现

  • 38例患者出现PSA反应(62%,95%CI 50-78)。
  • 单因素分析中反应者ABI Cmin为12.0 ng/mL(95%CI 9.4-15.6),无反应者为8.0 ng/mL(95%CI 5.8-11.6),反应者较无反应者高1.5倍(P=0.0015)。
  • 多因素分析仅ABI Cmin与PSA反应独立相关(OR=1.12,95%CI 1.01-1.25,P=0.004)。
  • 受试者工作特征分析显示ABI Cmin最佳阈值为8.4 ng/mL。
  • ABI Cmin高于8.4 ng/mL者无进展生存期显著更长(HR=0.55,95%CI 0.31-0.99),12.2个月(95%CI 9.2-19.5)vs 7.4个月(95%CI 5.5-14.7),P=0.044。

关键数值与推荐

  • ABI Cmin与PSA反应独立相关的OR=1.12(95%CI 1.01-1.25,P=0.004)。
  • ABI Cmin预测PSA反应的最佳阈值为8.4 ng/mL。
  • ABI Cmin高于8.4 ng/mL者无进展生存期HR=0.55(95%CI 0.31-0.99,P=0.044)。

临床怎么用

  • 作者认为阿比特龙浓度监测是改善转移性去势抵抗性前列腺癌患者临床结局的新方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abiraterone (ABI) is a major oral agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients but its systemic exposure is subject to a large inter-individual variability. We aimed to explore the relationship between ABI trough plasma concentration and prostate-specific antigen (PSA) response in mCRPC patients and to identify the critical determinants for its activity. PATIENTS AND METHODS: This is a monocentric prospective observational study in mCRPC patients treated with ABI. The plasmatic concentration of ABI at steady state was measured using liquid chromatography with fluorescence detection. The primary objective was to study the relationship between mean ABI plasma exposure (ABI Cmin) and 3-month PSA response. RESULTS: From 2012 to 2016, 61 mCRPC patients were eligible for pharmacokinetic/pharmacodynamic assessment. Thirty-eight patients experienced PSA response (62%, [confidence interval {CI} 95% 50-78]). In univariate analysis, ABI Cmin was 1.5-fold higher in responders: 12.0 ng/mL (CI 95% 9.4-15.6) versus 8.0 ng/mL (CI 95% 5.8-11.6; P = 0.0015). In multivariate analysis, only ABI Cmin was independently associated with PSA response (odds ratio = 1.12 [CI 95% 1.01-1.25], P = 0.004). By receiver operating characteristic analysis, the optimal threshold for ABI Cmin was 8.4 ng/mL. Progression-free survival (PFS) was significantly higher in patients with ABI Cmin above 8.4 ng/mL (hazard ratio 0.55, [CI 95% 0.31-0.99], 12.2 [CI 95% 9.2-19.5] versus 7.4 [CI 95% 5.5-14.7] months otherwise, P = 0.044). CONCLUSIONS: We showed that ABI trough concentration correlates with PSA response and PFS. Moreover, we could determine a cut-off value of plasmatic concentration for PSA response. Altogether, ABI concentration monitoring appears as a new approach to improve clinical outcome in mCPRC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carton E, Noe G, Huillard O, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer. 2016. PMID: 28027516. doi:10.1016/j.ejca.2016.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。